# Immunotherapy SBRT Sensitization of the Programmed Death-1 (PD-1) Effect

> **NCT03825510** · PHASE2 · COMPLETED · sponsor: **Crozer-Keystone Health System** · enrollment: 3 (actual)

## Conditions studied

- Metastatic Nonsmall Cell Lung Cancer
- Non Small Cell Lung Cancer

## Interventions

- **RADIATION:** Stereotactic Body Radiotherapy

## Key facts

- **NCT ID:** NCT03825510
- **Lead sponsor:** Crozer-Keystone Health System
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-04-28
- **Primary completion:** 2022-03-08
- **Final completion:** 2022-03-08
- **Target enrollment:** 3 (ACTUAL)
- **Last updated:** 2023-03-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03825510

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03825510, "Immunotherapy SBRT Sensitization of the Programmed Death-1 (PD-1) Effect". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03825510. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*